Summit Trail Advisors’s CONMED CNMD Stock Holding History

Summit Trail Advisors’s Portfolio CNMD Stock Details CNMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-4	Closed	–	–	682
2017 Q4	$0	Buy	+4	New	+$208	﹤0.01%	1989

Other funds holding CNMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CRM

Cramer Rosenthal McGlynn Stamford, Connecticut $1.36B AUM 31.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Summit Trail Advisors's CNMD Position: Q1 2018 in Review

Summit Trail Advisors sold out of CONMED (CNMD) in Q1 2018, closing a stake of 4 shares.

Summit Trail Advisors first reported a position in CNMD in Q4 2017 and held it in 1 quarter. The position peaked at $0 in Q4 2017. 173 funds tracked by Wall St. Rank hold CNMD as of Q1 2018.

Summit Trail Advisors reported no remaining CONMED position as of Q1 2018 after selling out during the quarter.
Summit Trail Advisors sold 4 CONMED shares in Q1 2018.
Summit Trail Advisors first reported a position in CONMED in Q4 2017 and held it in 1 quarter.
Summit Trail Advisors's CONMED position peaked at $0 in Q4 2017.
173 funds tracked by Wall St. Rank held CONMED as of Q1 2018.

Based on Summit Trail Advisors's 13F filing for Q1 2018, filed 21 May 2018.